LNC Therapeutics, based in Bordeaux, France, develops gut microbiota-directed drugs targeting obesity and associated cardiometabolic diseases. Its programs encompass fundamental research, preclinical studies and clinical trials. The company is led by CEO Jean-Luc Treillou and CSO Sandrine Claus, PhD. LNC raised €6.5m in a Series C to continue and expand its development efforts. Prior funding includes €1.5m in grants from French BPI and the Aquitaine Region. To date the company has raised a total of €16.5m.

Total raised

$12M

Funding rounds

2

Latest round

Series C

Latest activity

Sep 2017